- Home
- EVV vs SAVA Comparison
EVV vs SAVA Comparison
Compare EVV & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVV
- SAVA
- Stock Information
- Founded
- EVV 2003
- SAVA 1998
- Country
- EVV United States
- SAVA United States
- Employees
- EVV N/A
- SAVA N/A
- Industry
- EVV Finance/Investors Services
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- EVV Finance
- SAVA Health Care
- Exchange
- EVV Nasdaq
- SAVA Nasdaq
- Market Cap
- EVV 1.2B
- SAVA 112.6M
- IPO Year
- EVV N/A
- SAVA N/A
- Fundamental
- Price
- EVV $9.95
- SAVA $2.59
- Analyst Decision
- EVV
- SAVA Buy
- Analyst Count
- EVV 0
- SAVA 3
- Target Price
- EVV N/A
- SAVA $111.50
- AVG Volume (30 Days)
- EVV 323.7K
- SAVA 6.3M
- Earning Date
- EVV 01-01-0001
- SAVA 11-07-2024
- Dividend Yield
- EVV 9.66%
- SAVA N/A
- EPS Growth
- EVV N/A
- SAVA N/A
- EPS
- EVV N/A
- SAVA N/A
- Revenue
- EVV N/A
- SAVA N/A
- Revenue This Year
- EVV N/A
- SAVA N/A
- Revenue Next Year
- EVV N/A
- SAVA N/A
- P/E Ratio
- EVV N/A
- SAVA N/A
- Revenue Growth
- EVV N/A
- SAVA N/A
- 52 Week Low
- EVV $8.52
- SAVA $2.23
- 52 Week High
- EVV $10.07
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- EVV 38.02
- SAVA 24.85
- Support Level
- EVV $9.76
- SAVA $2.26
- Resistance Level
- EVV $10.30
- SAVA $2.68
- Average True Range (ATR)
- EVV 0.11
- SAVA 0.21
- MACD
- EVV -0.03
- SAVA 0.79
- Stochastic Oscillator
- EVV 29.36
- SAVA 34.29
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund may, as a secondary objective, also seek capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure among others.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.